IMMUNOTHERAPY WITH ELECTROFUSED DENDRITIC TUMOR HYBRIDS

电融合树突状肿瘤杂交体的免疫治疗

基本信息

  • 批准号:
    6763097
  • 负责人:
  • 金额:
    $ 34.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-07-01 至 2006-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Applicant's Abstract) The efficacy of cancer immunotherapy depends highly on the potency and duration of the induced immune response. To date, cancer vaccinations have utilized intact tumor cells, naive proteins, CTL-defined peptides, nucleic acids, cell membranes and recombinant viruses as well as genetically modified tumors. Although some approaches have been to increase the antigen presenting capacity of tumor cells, in most cases, the dominant role of host antigen-presenting cells (APCs) has been demonstrated. Among various APCs, dendritic cells (DCs) seem to have the essential properties required for eliciting T-cell responses: migration and homing, antigen processing and presentation and co-stimulation. Recently, DCs have been used to present tumor antigens. This is generally achieved by pulsing DCs with peptides, tumor lysates or RNA derived from neoplastic cells. It has also been demonstrated that immunization with DC-tumor fused chimeric cells results in the regression of established metastases. Fused cells should have the ability to elicit both MHC class I and II-restricted responses by processing and presenting known and undefined tumor antigens. In most reported cases, however, fusion has been accomplished with the use of PEG, resulting in low efficiency and high toxicity. With this approach, it may be the technical rather than conceptual aspects that limit its application. The applicant has recently demonstrated that fusion of DCs and tumor cells by applying electric field pulses is at least 10-fold more efficient than that by PEG. Interestingly, electrofusion of immature DCs with tumor cells resulted in hybrid cells having characteristics of mature DCs with high expression of MHC class II, B7.1 and B7.2 molecules. To analyze biological and immunological functions of these artificially generated chimeric cells, the current application will utilize the well-characterized model tumor-associated antigen, B-galactosidase, to address fundamental issues. Subsequent experiments will use several weakly and poorly immunogenic tumors. The goal of the current application is to develop in murine models, the principles and methodologies for utilizing DCs fused with entire tumor cells for active and adoptive immunotherapy of cancer. The specific aims are: 1) To optimize electrofusion techniques; 2) To characterize antigen processing and presentation, MHC restriction and trafficking patterns of fused cells; 3) To analyze characteristics of immune responses elicited by DC-tumor fused cells; 4) To explore the therapeutic potential of the chimeric cells; and 5) To develop methods for primary in vitro immunization for generating tumor-specific T cells.
(申请人摘要)肿瘤免疫治疗的疗效

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine.
  • DOI:
    10.1016/j.cellimm.2003.09.005
  • 发表时间:
    2003-10
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    J. Kjaergaard;K. Shimizu;S. Shu
  • 通讯作者:
    J. Kjaergaard;K. Shimizu;S. Shu
Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.
通过树突状细胞和肿瘤细胞的电融合产生的治疗性疫苗。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kuriyama,H;Shimizu,K;Lee,W;Kjaergaard,J;Parkhurst,MR;Cohen,PA;Shu,S
  • 通讯作者:
    Shu,S
Therapeutic immune response induced by electrofusion of dendritic and tumor cells.
  • DOI:
    10.1016/s0008-8749(03)00009-1
  • 发表时间:
    2002-11
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Hiroshi Tanaka;K. Shimizu;Takashi Hayashi;S. Shu
  • 通讯作者:
    Hiroshi Tanaka;K. Shimizu;Takashi Hayashi;S. Shu
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUYU SHU其他文献

SUYU SHU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUYU SHU', 18)}}的其他基金

Immunotherapy with Dendritic-Allogeneic Tumor Cells
树突状同种异体肿瘤细胞的免疫治疗
  • 批准号:
    7125606
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
Immunotherapy with Dendritic-Allogeneic Tumor Cells
树突状同种异体肿瘤细胞的免疫治疗
  • 批准号:
    6928007
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
Immunotherapy with Dendritic-Allogeneic Tumor Cells
树突状同种异体肿瘤细胞的免疫治疗
  • 批准号:
    7252652
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
Immunotherapy with Dendritic-Allogeneic Tumor Cells
树突状同种异体肿瘤细胞的免疫治疗
  • 批准号:
    6700500
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
Immunotherapy with Dendritic-Allogeneic Tumor Cells
树突状同种异体肿瘤细胞的免疫治疗
  • 批准号:
    7432446
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
Immunotherapy with Dendritic-Allogeneic Tumor Cells
树突状同种异体肿瘤细胞的免疫治疗
  • 批准号:
    7714833
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
IMMUNOTHERAPY WITH ELECTROFUSED DENDRITIC TUMOR HYBRIDS
电融合树突状肿瘤杂交体的免疫治疗
  • 批准号:
    6205329
  • 财政年份:
    2000
  • 资助金额:
    $ 34.43万
  • 项目类别:
IMMUNOTHERAPY WITH ELECTROFUSED DENDRITIC TUMOR HYBRIDS
电融合树突状肿瘤杂交体的免疫治疗
  • 批准号:
    6377653
  • 财政年份:
    2000
  • 资助金额:
    $ 34.43万
  • 项目类别:
IMMUNOTHERAPY WITH ELECTROFUSED DENDRITIC TUMOR HYBRIDS
电融合树突状肿瘤杂交体的免疫治疗
  • 批准号:
    6658985
  • 财政年份:
    2000
  • 资助金额:
    $ 34.43万
  • 项目类别:
IMMUNOTHERAPY WITH ELECTROFUSED DENDRITIC TUMOR HYBRIDS
电融合树突状肿瘤杂交体的免疫治疗
  • 批准号:
    6514261
  • 财政年份:
    2000
  • 资助金额:
    $ 34.43万
  • 项目类别:

相似海外基金

Senescence-associated-beta-galactosidase staining following traumatic brain injury
创伤性脑损伤后衰老相关β-半乳糖苷酶染色
  • 批准号:
    16K09220
  • 财政年份:
    2016
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
STUDIES OF CRYO-COOLING AND CATALYTIC MECHANISM IN E COLI BETA-GALACTOSIDASE
大肠杆菌β-半乳糖苷酶低温冷却及催化机制的研究
  • 批准号:
    7370342
  • 财政年份:
    2006
  • 资助金额:
    $ 34.43万
  • 项目类别:
CRYO-COOLING & CATALYTIC MECHANISM IN E COLI BETA GALACTOSIDASE
低温冷却
  • 批准号:
    6976241
  • 财政年份:
    2004
  • 资助金额:
    $ 34.43万
  • 项目类别:
Arabidopsis 2010: Collaborative Project on the Functional Genomics of Arabidopsis beta-Glucosidase and beta-Galactosidase Gene Families
拟南芥 2010:拟南芥 β-葡萄糖苷酶和 β-半乳糖苷酶基因家族功能基因组学合作项目
  • 批准号:
    0114666
  • 财政年份:
    2001
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Continuing Grant
Arabidopsis 2010: Collaborative Project on the Functional Genomics of Arabidopsis beta-Glucosidase and beta-Galactosidase Gene Families
拟南芥 2010:拟南芥 β-葡萄糖苷酶和 β-半乳糖苷酶基因家族功能基因组学合作项目
  • 批准号:
    0115937
  • 财政年份:
    2001
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Continuing Grant
THE GENE FOR HUMAN BETA GALACTOSIDASE-A
人类 β 半乳糖苷酶-A 基因
  • 批准号:
    6240154
  • 财政年份:
    1997
  • 资助金额:
    $ 34.43万
  • 项目类别:
THE GENE FOR HUMAN BETA GALACTOSIDASE-A
人类 β 半乳糖苷酶-A 基因
  • 批准号:
    6271626
  • 财政年份:
    1997
  • 资助金额:
    $ 34.43万
  • 项目类别:
Pathogenesis and Treatment of beta-Galactosidase-Deficient Knockout Mice
β-半乳糖苷酶缺陷型基因敲除小鼠的发病机制和治疗
  • 批准号:
    08457058
  • 财政年份:
    1996
  • 资助金额:
    $ 34.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
MOLECULAR ANALYSIS OF ACID BETA-GALACTOSIDASE
酸性 β-半乳糖苷酶的分子分析
  • 批准号:
    3464785
  • 财政年份:
    1993
  • 资助金额:
    $ 34.43万
  • 项目类别:
APPROACHES TO BETA-GALACTOSIDASE GENE EXPRESSION
β-半乳糖苷酶基因表达方法
  • 批准号:
    3055727
  • 财政年份:
    1991
  • 资助金额:
    $ 34.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了